A cutting-edge approach to identify and engineer genes responsible for natural product formation in non-model bacteria, enhancing the bioactivity and production of valuable compounds.
This innovative research focuses on the genetic engineering of non-model bacteria to discover and manipulate the genes responsible for natural product formation. By employing advanced genomic and transcriptomic analysis, combined with loss-of-function and gain-of-function screening, the research aims to validate the involvement of specific genes in the biosynthesis of valuable natural products. This process not only identifies key genetic elements but also enhances the production and bioactivity of these compounds, offering significant implications for pharmaceuticals, agriculture, and biotechnology.
Key features:
The technology is currently at TRL 4, indicating that it has been validated at the laboratory level, with ongoing efforts to refine the approach and advance towards more extensive validation and application.
Princeton University is a private, research-intensive university in Princeton, New Jersey, known for a tightly integrated campus and a globally connected research enterprise. Industry partners engage through a dedicated corporate relations team that brokers sponsored research, consortia, and talent pipelines. Co-located assets include shared user facilities for advanced imaging and nanofabrication, a university-managed U.S. Department of Energy national lab, and a research park that hosts corporate collaborators. Research is supported by competitive federal funding from agencies such as NSF, NIH, DOE, DoD, and NASA. A technology transfer office provides IP strategy, licensing, and startup support, complemented by an affiliated incubator and mentor network.